Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer

  • Ha, In-Bong (Department of Radiation Oncology, Gyeongsang National University School of Medicine) ;
  • Jeong, Bae-Kwon (Department of Radiation Oncology, Gyeongsang National University School of Medicine) ;
  • Jeong, Hojin (Department of Radiation Oncology, Gyeongsang National University School of Medicine) ;
  • Choi, Hoon-Sik (Department of Radiation Oncology, Gyeongsang National University School of Medicine) ;
  • Chai, Gyu-Young (Department of Radiation Oncology, Gyeongsang National University School of Medicine) ;
  • Kang, Myoung-Hee (Institute of Health Science, Gyeongsang National University) ;
  • Kim, Hoon Gu (Institute of Health Science, Gyeongsang National University) ;
  • Lee, Gyeong-Won (Institute of Health Science, Gyeongsang National University) ;
  • Na, Jae-Beom (Institute of Health Science, Gyeongsang National University) ;
  • Kang, Ki-Mun (Department of Radiation Oncology, Gyeongsang National University School of Medicine)
  • Received : 2013.08.08
  • Accepted : 2013.10.16
  • Published : 2013.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We evaluated the effect of early chemoradiotherapy on the treatment of patients with limited stage small cell lung cancer (LS-SCLC). Materials and Methods: Between January 2006 and December 2011, thirty-one patients with histologically proven LS-SCLC who were treated with two cycles of chemotherapy followed by concurrent chemoradiotherapy and consolidation chemotherapy were retrospectively analyzed. The chemotherapy regimen was composed of etoposide and cisplatin. Thoracic radiotherapy consisted of 50 to 60 Gy (median, 54 Gy) given in 5 to 6.5 weeks. Results: The follow-up period ranged from 5 to 53 months (median, 22 months). After chemoradiotherapy, 35.5% of the patients (11 patients) showed complete response, 61.3% (19 patients) showed partial response, 3.2% (one patient) showed progressive disease, resulting in an overall response rate of 96.8% (30 patients). The 1-, 2-, and 3-year overall survival (OS) rates were 66.5%, 41.0%, and 28.1%, respectively, with a median OS of 21.3 months. The 1-, 2-, and 3-year progression free survival (PFS) rates were 49.8%, 22.8%, and 13.7%, respectively, with median PFS of 12 months. The patterns of failure were: locoregional recurrences in 29.0% (nine patients), distant metastasis in 9.7% (three patients), and both locoregional and distant metastasis in 9.7% (three patients). Grade 3 or 4 toxicities of leukopenia, anemia, and thrombocytopenia were observed in 32.2%, 29.0%, and 25.8%, respectively. Grade 3 radiation esophagitis and radiation pneumonitis were shown in 12.9% and 6.4%, respectively. Conclusion: We conclude that early chemoradiotherapy for LS-SCLC provides feasible and acceptable local control and safety.

Keywords

References

  1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44. https://doi.org/10.1200/JCO.2005.04.4859
  2. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987;106:655-62. https://doi.org/10.7326/0003-4819-106-5-655
  3. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-8. https://doi.org/10.1056/NEJM198704093161504
  4. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24. https://doi.org/10.1056/NEJM199212033272302
  5. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-5. https://doi.org/10.1200/JCO.1992.10.6.890
  6. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006;17:543-52. https://doi.org/10.1093/annonc/mdj094
  7. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60. https://doi.org/10.1200/JCO.2002.12.071
  8. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow up. J Clin Oncol 2002;20:4665-72. https://doi.org/10.1200/JCO.2002.12.111
  9. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15. https://doi.org/10.1054/bjoc.2000.1164
  10. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-44.
  11. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900.
  12. Su J, Zhu S, Liu Z, Jing S, Shen W, Li J. Prognostic analysis of limited-stage small cell lung cancer after chemoradiotherapy. Onkologie 2012;35:362-7. https://doi.org/10.1159/000338962
  13. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837-45. https://doi.org/10.1200/JCO.2004.01.178
  14. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999;17:2681-91. https://doi.org/10.1200/JCO.1999.17.9.2681
  15. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Bioi Phys 2004;59:943-51. https://doi.org/10.1016/j.ijrobp.2004.01.055
  16. Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist 2010;15:187-95. https://doi.org/10.1634/theoncologist.2009-0298
  17. Spiro SG, James LE, Rudd RM, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 2006;24:3823-30. https://doi.org/10.1200/JCO.2005.05.3181
  18. Tannock IF. Treatment of cancer with radiation and drugs. J Clin OncoI 1996;14:3156-74. https://doi.org/10.1200/JCO.1996.14.12.3156
  19. Sohn HJ, Kim SW, Ahn JH, et al. Concurrent etoposide/cisplatin combination chemotherapy (EP) and thoracic radiotherapy after two cycles of EP for limited stage small cell lung cancer. Cancer Res Treat 2002;34:409-15. https://doi.org/10.4143/crt.2002.34.6.409
  20. Kong FM, Lally BE, Chang JY, et al. ACR Appropriateness Criteria radiation therapy for small-cell lung cancer. Am J Clin OncoI 2013;36:206-13. https://doi.org/10.1097/COC.0b013e31827e5523
  21. Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twicedaily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16: 3528-36. https://doi.org/10.1200/JCO.1998.16.11.3528
  22. Roof KS, Fidias P, Lynch TJ, Ancukiewicz M, Choi NC. Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Bioi Phys 2003;57:701-8. https://doi.org/10.1016/S0360-3016(03)00715-6
  23. Bogart JA, Herndon JE 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Bioi Phys 2004;59:460-8. https://doi.org/10.1016/j.ijrobp.2003.10.021
  24. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71. https://doi.org/10.1056/NEJM199901283400403
  25. Yeo SG, Cho MJ, Kim SY, Kim KW, Kim JS. Twice daily radiation therapy plus concurrent chemotherapy for limited-stage small cell lung cancer. J Korean Soc Ther Radiol Oncol 2006;24:96-102.
  26. Salama JK, Hodgson L, Pang H, et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinumbased chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol 2013;8:1043-9. https://doi.org/10.1097/JTO.0b013e318293d8a4
  27. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:3248-54. https://doi.org/10.1200/JCO.2004.11.089
  28. van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010;77:329-36. https://doi.org/10.1016/j.ijrobp.2009.04.075

Cited by

  1. Relationship Between the SER Treatment Period and Prognosis of Patients with Small Cell Lung Cancer vol.15, pp.15, 2013, https://doi.org/10.7314/apjcp.2014.15.15.6415
  2. Combination effects of tissue heterogeneity and geometric targeting error in stereotactic body radiotherapy for lung cancer using CyberKnife vol.16, pp.5, 2013, https://doi.org/10.1120/jacmp.v16i5.5397
  3. Effects of Definitive Chemoradiotherapy on Respiratory Function Tests and Quality of Life Scores During Treatment of Lung Cancer vol.16, pp.15, 2015, https://doi.org/10.7314/apjcp.2015.16.15.6779
  4. Early treatment volume reduction rate as a prognostic factor in patients treated with chemoradiotherapy for limited stage small cell lung cancer vol.33, pp.2, 2013, https://doi.org/10.3857/roj.2015.33.2.117
  5. Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer : A single-centre retrospective study vol.193, pp.2, 2017, https://doi.org/10.1007/s00066-016-1069-6
  6. Patterns of care and survival among small cell lung cancer patients: Experience from a tertiary center in India vol.29, pp.1, 2017, https://doi.org/10.1016/j.jnci.2016.10.001